Compare Stocks: IXHL vs. UPC vs. AKAN vs. BIOA
Compare normalized stock price performance over 6 months, 1 year or 2 years. Each line starts at 0%, so different stock prices can be compared on the same scale.
IXHLUPCAKANBIOA
Market Snapshot
Current market context for the selected companies.
IXHL
$3.74
Market Cap
$44.27M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Data through
2026-08-26
UPC
$5.25
Market Cap
$3.53M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Data through
2026-08-26
AKAN
$4.21
Market Cap
$2.29M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Data through
2026-08-26
BIOA
$9.83
Market Cap
$451.63M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Data through
2026-08-26
Performance
Absolute returns and relative performance versus SPY.
| Metric | IXHL | UPC | AKAN | BIOA |
|---|---|---|---|---|
| 1 Month | +26.4% | +64.6% | -32.1% | -55.2% |
| 1 Month vs SPY | +23.0% | +61.3% | -35.4% | -58.5% |
| 3 Months | +15.1% | +84.2% | -80.6% | -42.0% |
| 3 Months vs SPY | +13.1% | +82.2% | -82.6% | -44.0% |
| 6 Months | -21.6% | +78.0% | +3.4% | -55.6% |
| 6 Months vs SPY | -32.0% | +67.5% | -7.1% | -66.0% |
| 1 Year | -83.2% | +47.5% | -95.1% | +118.0% |
| 1 Year vs SPY | -102.3% | +28.3% | -114.2% | +98.8% |
| 2 Years | -93.4% | -99.7% | -97.9% | — |
| 2 Years vs SPY | -129.9% | -136.3% | -134.5% | — |
Growth & Profitability
Operating growth, margins and capital efficiency.
Valuation
Common valuation multiples shown side by side.
Cash Flow & Balance Sheet
Cash generation and leverage context.
Earnings Outlook
Upcoming earnings expectations when available.